non typeable haemophilus influenzae  (ATCC)

Journal: Frontiers in Public Health

Article Title: Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review

doi: 10.3389/fpubh.2025.1544359

Figure Lengend Snippet: Serotype distribution in invasive pneumococcal disease among children ≤5 years of age (A) post-PHiD-CV/PCV13 implementation through infant national immunization programs ( n = 32), (B) post-PHiD-CV ( n = 7), and (C) post-PCV13 ( n = 31) uptake in infants (either through infant national immunization programs or private markets). The top 20 serotypes are shown. Serotypes are represented by colors corresponding to the lowest valency PCV product in which they are included. In the PCV legend, the additional serotypes included in the product are relative to the next lower valency product. Pooled percentage averages were calculated for each serotype individually, thus the sum of all serotypes may exceed 100%. For panel A , serotype-specific pooled percentage averages were calculated only if 5 or more studies reported on the respective serotype. For panel B and C , the pooled percentage averages were calculated irrespective of the number of studies reporting on it. For panel B , although the legend includes all PCVs, no PHiD-CV-specific serotypes were identified in the top-20 serotypes. IPD, invasive pneumococcal disease; n , number of studies that were included in the analysis; NIP, national immunization program; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV; PHiD-CV, pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.

Article Snippet: The pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix , GSK) and 13-valent PCV (PCV13, Prevenar 13/Prevnar 13 , Pfizer Inc.) replaced PCV7 in NIPs since 2009 and provided coverage for additional serotypes (PHiD-CV contains all PCV7 serotypes + 1, 5, and 7F; PCV13 contains all PHiD-CV serotypes + 3, 6A, and 19A) ( ).

Techniques:

Journal: Frontiers in Public Health

Article Title: Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review

doi: 10.3389/fpubh.2025.1544359

Figure Lengend Snippet: Serotype distribution in acute otitis media among children ≤5 years of age (A) post-PHiD-CV/PCV13 implementation through infant national immunization programs ( n = 8), (B) post-PHiD-CV ( n = 2), and (C) post-PCV13 ( n = 5) uptake in infants (either through infant national immunization programs or private markets). The top 20 serotypes are shown. Serotypes are represented by colors corresponding to the lowest valency PCV product in which they are included. In the PCV legend, the additional serotypes included in the product are relative to the next lower valency product. Pooled percentage averages were calculated for each serotype individually, thus the sum of all serotypes may exceed 100%. For panel A , serotype-specific pooled percentage averages were calculated only if 5 or more studies reported on the respective serotype. For panel B and C , the pooled percentage averages were calculated irrespective of the number of studies reporting on it. AOM, acute otitis media; n , number of studies that were included in the analysis; NIP, national immunization program; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV; PHiD-CV, pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.

Article Snippet: The pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix , GSK) and 13-valent PCV (PCV13, Prevenar 13/Prevnar 13 , Pfizer Inc.) replaced PCV7 in NIPs since 2009 and provided coverage for additional serotypes (PHiD-CV contains all PCV7 serotypes + 1, 5, and 7F; PCV13 contains all PHiD-CV serotypes + 3, 6A, and 19A) ( ).

Techniques:

Journal: Frontiers in Public Health

Article Title: Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review

doi: 10.3389/fpubh.2025.1544359

Figure Lengend Snippet: Serotype distribution in community-acquired pneumonia among children ≤5 years of age post-PHiD-CV/-PCV13 implementation through infant national immunization programs ( n = 3). The top 20 serotypes are shown. Serotypes are represented by colors corresponding to the lowest valency PCV product in which they are included. In the PCV legend, the additional serotypes included in the product are relative to the next lower valency product. Pooled percentage averages were calculated for each serotype individually, thus the sum of all serotypes may exceed 100%. Serotype-specific pooled percentage averages were calculated irrespective of the number of studies reporting on it. Given the limited number of studies on CAP, results from the subgroup analyses per PCV product need to be interpreted with caution and are included in the . CAP, community-acquired pneumonia; n, number of studies that were included in the analysis; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PHiD-CV, pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine; PCV13, 13-valent PCV.

Article Snippet: The pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix , GSK) and 13-valent PCV (PCV13, Prevenar 13/Prevnar 13 , Pfizer Inc.) replaced PCV7 in NIPs since 2009 and provided coverage for additional serotypes (PHiD-CV contains all PCV7 serotypes + 1, 5, and 7F; PCV13 contains all PHiD-CV serotypes + 3, 6A, and 19A) ( ).

Techniques: